

Product Name: Recombinant Nipah virus/NiV F/Fusion glycoprotein F0 Protein, N-His
Catalog #: PEX10966



Summary

Name	Nipah virus/NiV F/Fusion glycoprotein F0 Protein
Purity	>90% as determined by SDS-PAGE.
Endotoxin level	Please contact with the lab for this information.
Construction	Gly131-Thr546
Accession #	Q9IH63
Host	E. coli
Species	Nipah virus (NiV)
Predicted Molecular Mass	48.43 kDa
Formulation	Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.
Shipping	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability&Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Alternative Names

Nipah virus/NiV F/Fusion glycoprotein F0 Protein

Background

Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus, mediates host cell entry through the coordinated action of two envelope glycoproteins: the attachment glycoprotein (G), which engages the host cell receptors ephrin-B2 and ephrin-B12, and the fusion glycoprotein (F), which drives membrane fusion following receptor binding. These viral surface proteins, along with the viral RNA-dependent RNA polymerase (RdRp) complex comprising the nucleoprotein (N), phosphoprotein (P), and large polymerase protein (L), constitute the primary molecular targets for therapeutic intervention and vaccine development. The conserved receptor-binding interface of the G protein and the fusion machinery of the F protein represent particularly attractive targets for neutralizing antibodies and entry inhibitors, while the viral replication machinery offers potential targets for broad-spectrum antiviral compounds targeting paramyxovirus transcription and replication.

**Product Name: Recombinant Nipah virus/NiV F/Fusion
glycoprotein F0 Protein, N-His
Catalog #: PEX10966**



Note

For Research Use Only , Not for Diagnostic Use.